Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the ...

Eli Lilly LLY announced that it is increasing its manufacturing capacity in the United States by building four new plants.

Lilly plans to build four new pharmaceutical plants in the US, creating 13,000 jobs and bringing its recent domestic ...

Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.

EastGroup Properties, Inc.  (the "Company", "we", "our", "us" or "EastGroup") announced today its recent business activity. As ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Eli Lilly (LLY) joins hands with Magnet Biomedicine in a deal worth up to $1.25B to develop cancer drugs using Magnet's ...

Magnet Biomedicine, a leading biopharmaceutical company advancing molecular glue discovery with rational selection and design ...

Eli Lilly is making a massive $50 billion investment in U.S. manufacturing. This move more than doubles their previous $23 ...